White Paper

Process Characterization: Ready For The FDA? (Article)

By Greg Sears, Head of Manufacturing Science and Technology, Pharma Services, Biologics, Thermo Fisher Scientific

Sterile pharma manufacturing discovery 450x300

Prior to the 2011 release of the FDA guidance on process characterization,1 the pharmaceutical industry historically viewed process characterization, the validation of a manufacturing process to minimize risk and ensure consistent quality throughout a product’s life cycle, as optional. As pipelines evolved to more complex molecules and manufacturing processes, though, the outlook of regulatory agencies on process characterization also changed. Today, they see process characterization as an essential step in the commercialization of a new drug product. This is related to various benefits of process characterization, such as enhancing not only process understanding but also, and most importantly, patient safety. Realizing these benefits and more requires proper planning and application of a comprehensive process characterization strategy.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: